[Atrial fibrillation in elderly]

Area of Science:

• Cardiology
• Neurology
• Pharmacology

Context:

• Atrial fibrillation (AF) is a common condition in the elderly, significantly elevating the risk of ischemic stroke.
• Ischemic strokes in patients with AF tend to be more severe.
• Vitamin K antagonists (VKAs) are effective stroke preventatives but carry a notable hemorrhagic risk.

Purpose:

• To evaluate the efficacy and safety of new oral anticoagulants (NOACs) compared to traditional therapies for stroke prevention in patients with atrial fibrillation.
• To provide evidence-based recommendations for anticoagulant selection in AF patients.

Summary:

• New oral anticoagulants, including direct thrombin inhibitors (e.g., dabigatran) and direct factor Xa inhibitors (e.g., rivaroxaban, apixaban), have demonstrated non-inferior or superior efficacy to VKAs in preventing stroke.
• These NOACs exhibit a significantly better safety profile, particularly concerning the risk of intracranial hemorrhage.
• The findings support the preferential use of NOACs for the vast majority of AF patients, with individualized drug and dosage selection.

Impact:

• Recommends prioritizing NOACs for stroke prevention in most AF patients due to improved safety and comparable or better efficacy.
• Highlights the need for personalized treatment strategies based on individual patient factors when selecting anticoagulants and dosages.